Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development. Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego. Presentations include real-world evidence […]
ADA 2023
France expands reimbursement for Abbott FreeStyle Libre 2 to all basal insulin users
Abbott (NYSE:ABT) announced today that the French health authority approved the expansion of reimbursement coverage for the FreeStyle Libre 2. FreeStyle Libre 2 previously only had coverage for people with type 1 and type 2 diabetes who require intensive insulin therapy. France’s expansion covers the continuous glucose monitor (CGM) for all people who use basal […]
Real-world data supports Bigfoot Biomedical diabetes management platform
Bigfoot Biomedical today announced study data demonstrating the potential of its Bigfoot Unity system for diabetes management. The FDA-cleared Bigfoot Unity platform aims to simplify continuous glucose monitors (CGMs) and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin […]
